MedCity News February 12, 2024
Frank Vinluan

Acquiring CymaBay Therapeutics gives Gilead Sciences another drug for its liver disease portfolio. CymaBay’s molecule, seladelpar, is under FDA review for treating primary biliary cholangitis, a rare disease affecting the bile ducts of the liver.

Gilead Sciences is acquiring biotech company CymaBay Therapeutics in a $4.3 billion deal that comes with a drug candidate currently under FDA review in a rare liver disease with few treatments.

According to deal terms announced Monday, Gilead will pay $32.50 cash for each share of CymaBay. That price is a 27% premium to CymaBay’s closing stock price on Friday. The acquisition marks a comeback for the company and its drug, which just a few years ago faced an uncertain future amid safety questions.

The...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Mergers & Acquisitions / JV, Pharma / Biotech, Trends
Related Articles:
Pharma Pulse 11/25/24: Deepening Patient Relationships, Menopause May Increase Risk of Asthma & more
Axolotl Biosciences Brings Biotech to the Forefront at Formnext 2024
Innovative approach maps gene activity in the living human brain
Trump tariffs could drive up generic drug costs: 5 takeaways
Answer ALS, Cedars-Sinai Collaboration, Single-Cell Protein Profiling, ChapsVision Acquires Sinequa, More

Share This Article